Chinook Therapeutics, Inc. – NASDAQ:KDNY
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Chinook Therapeutics stock price monthly change
+6.46%
month
Chinook Therapeutics stock price quarterly change
+74.62%
quarter
Chinook Therapeutics stock price yearly change
+96.93%
year
Chinook Therapeutics key metrics
Market Cap | 2.70B |
Enterprise value | 1.33B |
P/E | -7 |
EV/Sales | 217.79 |
EV/EBITDA | -7.48 |
Price/Sales | 230.19 |
Price/Book | 3.19 |
PEG ratio | 0.23 |
EPS | -3.48 |
Revenue | 5.84M |
EBITDA | -221.24M |
Income | -243.21M |
Revenue Q/Q | 141.14% |
Revenue Y/Y | -89.23% |
Profit margin | -3065.68% |
Oper. margin | -2824.67% |
Gross margin | 0% |
EBIT margin | -2824.67% |
EBITDA margin | -3782.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChinook Therapeutics stock price history
Chinook Therapeutics stock forecast
Chinook Therapeutics financial statements
| Sep 2022 | 2.50M | -54.28M | -2170.69% |
|---|---|---|---|
| Dec 2022 | 512K | -61.8M | -12070.31% |
| Mar 2023 | 1.82M | -60.17M | -3291.96% |
| Jun 2023 | 1.00M | -66.94M | -6641.27% |
| Sep 2022 | 590336000 | 115.7M | 19.6% |
|---|---|---|---|
| Dec 2022 | 574084000 | 132.14M | 23.02% |
| Mar 2023 | 543875000 | 131.48M | 24.18% |
| Jun 2023 | 488811000 | 131.77M | 26.96% |
| Sep 2022 | -25.31M | -13.13M | 18.83M |
|---|---|---|---|
| Dec 2022 | -36.82M | 2.47M | 23.69M |
| Mar 2023 | -50.66M | 32.43M | 21.26M |
| Jun 2023 | -61.19M | 68.00M | 2.01M |
Chinook Therapeutics alternative data
| Aug 2023 | 214 |
|---|---|
| Sep 2023 | 214 |
| Oct 2023 | 214 |
| Nov 2023 | 214 |
| Dec 2023 | 214 |
| Jan 2024 | 214 |
| Feb 2024 | 214 |
| Mar 2024 | 214 |
| Apr 2024 | 214 |
| May 2024 | 214 |
| Jun 2024 | 214 |
| Jul 2024 | 214 |
Chinook Therapeutics other data
33.33%
-52.47%
of KDNY is owned by hedge funds
92
-58
21.45M
-36.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 10000 | 0 |
| Oct 2022 | 0 | 10917 |
| Nov 2022 | 0 | 10000 |
| Dec 2022 | 0 | 45770 |
| Jan 2023 | 0 | 53389 |
| Feb 2023 | 0 | 15046 |
| Mar 2023 | 0 | 400000 |
| Apr 2023 | 0 | 321732 |
| May 2023 | 0 | 1155 |
| Aug 2023 | 0 | 1168 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | KING ANDREW JAMES officer: Chief Scientific Officer | Common Stock | 1,168 | $39.03 | $45,586 | ||
Option | KING ANDREW JAMES officer: Chief Scientific Officer | Common Stock | 3,333 | N/A | N/A | ||
Option | KING ANDREW JAMES officer: Chief Scientific Officer | Restricted Stock Units | 3,333 | N/A | N/A | ||
Sale | GREENMAN WILLIAM MARINER director | Common Stock | 1,155 | $23.3 | $26,912 | ||
Option | GREENMAN WILLIAM MARINER director | Common Stock | 3,300 | N/A | N/A | ||
Option | GREENMAN WILLIAM MARINER director | Restricted Stock Units | 3,300 | N/A | N/A | ||
Option | AKKARAJU SRINIVAS director | Common Stock | 3,300 | N/A | N/A | ||
Option | AKKARAJU SRINIVAS director | Restricted Stock Units | 3,300 | N/A | N/A | ||
Option | HAGHIGHAT ROSS director | Common Stock | 3,300 | N/A | N/A | ||
Option | HAGHIGHAT ROSS director | Restricted Stock Units | 3,300 | N/A | N/A |
Calliditas: A Trailblazing Triumph In IgAN Treatment
Chinook: CHK-336 Trial Pause Creates Buying Opportunity, All Eyes On IgAN Readout
Chinook: Travere's Sparsentan Approval Is Net Positive
Travere: Sparsentan Approval Is Likely, But Future Is Uncertain
Chinook's Atrasentan: A Promising Solution For IgA Nephropathy?
Vera: Disappointing Data From Phase 2 ORIGIN Trial, Initiating Coverage With A Sell Rating
Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts
Chinook Therapeutics: Multiple Shots On Goal For IgAN
Checking Out Chinook Therapeutics
-
When is Chinook Therapeutics's next earnings date?
Unfortunately, Chinook Therapeutics's (KDNY) next earnings date is currently unknown.
-
Does Chinook Therapeutics pay dividends?
No, Chinook Therapeutics does not pay dividends.
-
How much money does Chinook Therapeutics make?
Chinook Therapeutics has a market capitalization of 2.70B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 88.13% to 6.13M US dollars.
-
What is Chinook Therapeutics's stock symbol?
Chinook Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KDNY".
-
What is Chinook Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Chinook Therapeutics?
Shares of Chinook Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Chinook Therapeutics's key executives?
Chinook Therapeutics's management team includes the following people:
- Mr. Eric L. Dobmeier Pres, Chief Executive Officer & Director(age: 56, pay: $695,910)
- Dr. Alan Glicklich M.D. Chief Medical Officer(age: 63, pay: $437,050)
- Mr. Tom Frohlich Chief Operating Officer(age: 49, pay: $426,430)
-
How many employees does Chinook Therapeutics have?
As Jul 2024, Chinook Therapeutics employs 214 workers.
-
When Chinook Therapeutics went public?
Chinook Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 6 Oct 2020.
-
What is Chinook Therapeutics's official website?
The official website for Chinook Therapeutics is chinooktx.com.
-
Where are Chinook Therapeutics's headquarters?
Chinook Therapeutics is headquartered at 400 Fairview Avenue North, Seattle, WA.
-
How can i contact Chinook Therapeutics?
Chinook Therapeutics's mailing address is 400 Fairview Avenue North, Seattle, WA and company can be reached via phone at +20 64 857241.
Chinook Therapeutics company profile:
Chinook Therapeutics, Inc.
chinooktx.comExchange:
NASDAQ
Full time employees:
214
Industry:
Biotechnology
Sector:
Healthcare
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
400 Fairview Avenue North
Seattle, WA 98109
Seattle, WA 98109
CIK: 0001435049
ISIN: US00739L1017
CUSIP: 16961L106
